Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on &#8805; 1 line of endocrine therapy: systematic review and meta-analysis.

Huang, Xiewei; Yu, Yushuai; Luo, Shiping; Fu, Wenfen; Zhang, Jie; Song, Chuangui

Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis.

Huang, Xiewei; Yu, Yushuai; Luo, Shiping; Fu, Wenfen; Zhang, Jie; Song, Chuangui.

Affiliation

Huang X; Department of Breast Surgery, Fujian Medical University Union Hospital, No. 29, Xin Quan Road, Gulou District, 350001, Fuzhou, Fujian Province, China.
Yu Y; Breast Surgery Institute, Fujian Medical University, 350001, Fuzhou, Fujian Province, China.
Luo S; Department of Breast Surgery, Fujian Medical University Union Hospital, No. 29, Xin Quan Road, Gulou District, 350001, Fuzhou, Fujian Province, China.
Fu W; Breast Surgery Institute, Fujian Medical University, 350001, Fuzhou, Fujian Province, China.
Zhang J; Department of Breast Surgery, Fujian Medical University Union Hospital, No. 29, Xin Quan Road, Gulou District, 350001, Fuzhou, Fujian Province, China.
Song C; Breast Surgery Institute, Fujian Medical University, 350001, Fuzhou, Fujian Province, China.

BMC Cancer ; 24(1): 205, 2024 Feb 13.

Article de En | MEDLINE | ID: mdl-38350924

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Systematic_reviews Langue: En Journal: BMC Cancer Sujet du journal: NEOPLASIAS Année: 2024 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google